药品信息速递

订阅

MedSci主页 / 所有栏目 / 药品信息速递

欧盟批准AZ的Fasenra治疗严重哮喘

2018-01-11 MedSci MedSci原创

Fasenra严重哮喘
关注

阿斯利康(AstraZeneca)的biologic Fasenra在欧洲被批准用于治疗严重嗜酸粒细胞性哮喘。具体而言，尽管高剂量吸入皮质类固醇加长效β受体激动剂，但该药物的标签允许其在成人中的使用得到充分控制。阿斯利康说，Fasenra（benralizumab）是第一个获得批准的呼吸类生物制剂，它是一种招募自然杀伤细胞以消耗嗜酸性粒细胞的单克隆抗体，在体内维持药效的时间长达八周。批准是基于WI

阿斯利康(AstraZeneca)的biologic Fasenra在欧洲被批准用于治疗严重嗜酸粒细胞性哮喘。具体而言，尽管高剂量吸入皮质类固醇加长效β受体激动剂，但该药物的标签允许其在成人中的使用得到充分控制。阿斯利康说，Fasenra（benralizumab）是第一个获得批准的呼吸类生物制剂，它是一种招募自然杀伤细胞以消耗嗜酸性粒细胞的单克隆抗体，在体内维持药效的时间长达八周。批准是基于WINDWARD计划的结果，包括关键的III期加重试验，SIROCCO和CALIMA，以及ZONDA的III期OCS保留试验。SIROCCO和CALIMA的结果显示，每年哮喘发作率降低高达51%，而肺功能的改善与FEV1的变化有关，在第一次给予治疗剂量的benralizumab 4周后，FEV1的变化达到159毫升，且整个治疗周期都维持在该水平。此外，哮喘症状有改善，如气喘、咳嗽、胸闷和气短，在两种试验中，benralizumab治疗的患者和安慰剂组患者的不良反应频率相似。英国诺丁汉大学哮喘和呼吸内科教授Tim Harrison说："许多患有严重嗜酸性哮喘的患者会出现虚弱的症状，并会增加急诊、住院

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2057947, encodeId=581e205e9474f, content=<a href='/topic/show?id=3836e24819' target=_blank style='color:#2F92EE;'>#FAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7248, encryptionId=3836e24819, topicName=FAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Wed Jun 27 12:06:00 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717835, encodeId=7e2a1e17835ea, content=<a href='/topic/show?id=e40c2116554' target=_blank style='color:#2F92EE;'>#严重哮喘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21165, encryptionId=e40c2116554, topicName=严重哮喘)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4b932466782, createdName=lujian, createdTime=Sat Apr 21 02:06:00 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1714758, encodeId=98371e14758db, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e5031899089, createdName=12498e5fm22(暂无昵称), createdTime=Sat Mar 17 19:06:00 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271166, encodeId=04c212e1166d7, content=<a href='/topic/show?id=a2bee24989' target=_blank style='color:#2F92EE;'>#Fasenra#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7249, encryptionId=a2bee24989, topicName=Fasenra)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb0b97, createdName=zhangxingru, createdTime=Sat Jan 13 13:06:00 CST 2018, time=2018-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589982, encodeId=55e915899822e, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63118, encryptionId=2d1c63118e9, topicName=欧盟批准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0d617780998, createdName=chenwq14, createdTime=Sat Jan 13 13:06:00 CST 2018, time=2018-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277630, encodeId=eba62e7630d2, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Thu Jan 11 22:28:13 CST 2018, time=2018-01-11, status=1, ipAttribution=)]
    2018-06-27 gracezdd

    #FAS#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2057947, encodeId=581e205e9474f, content=<a href='/topic/show?id=3836e24819' target=_blank style='color:#2F92EE;'>#FAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7248, encryptionId=3836e24819, topicName=FAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Wed Jun 27 12:06:00 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717835, encodeId=7e2a1e17835ea, content=<a href='/topic/show?id=e40c2116554' target=_blank style='color:#2F92EE;'>#严重哮喘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21165, encryptionId=e40c2116554, topicName=严重哮喘)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4b932466782, createdName=lujian, createdTime=Sat Apr 21 02:06:00 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1714758, encodeId=98371e14758db, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e5031899089, createdName=12498e5fm22(暂无昵称), createdTime=Sat Mar 17 19:06:00 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271166, encodeId=04c212e1166d7, content=<a href='/topic/show?id=a2bee24989' target=_blank style='color:#2F92EE;'>#Fasenra#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7249, encryptionId=a2bee24989, topicName=Fasenra)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb0b97, createdName=zhangxingru, createdTime=Sat Jan 13 13:06:00 CST 2018, time=2018-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589982, encodeId=55e915899822e, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63118, encryptionId=2d1c63118e9, topicName=欧盟批准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0d617780998, createdName=chenwq14, createdTime=Sat Jan 13 13:06:00 CST 2018, time=2018-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277630, encodeId=eba62e7630d2, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Thu Jan 11 22:28:13 CST 2018, time=2018-01-11, status=1, ipAttribution=)]
    2018-04-21 lujian

    #严重哮喘#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2057947, encodeId=581e205e9474f, content=<a href='/topic/show?id=3836e24819' target=_blank style='color:#2F92EE;'>#FAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7248, encryptionId=3836e24819, topicName=FAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Wed Jun 27 12:06:00 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717835, encodeId=7e2a1e17835ea, content=<a href='/topic/show?id=e40c2116554' target=_blank style='color:#2F92EE;'>#严重哮喘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21165, encryptionId=e40c2116554, topicName=严重哮喘)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4b932466782, createdName=lujian, createdTime=Sat Apr 21 02:06:00 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1714758, encodeId=98371e14758db, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e5031899089, createdName=12498e5fm22(暂无昵称), createdTime=Sat Mar 17 19:06:00 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271166, encodeId=04c212e1166d7, content=<a href='/topic/show?id=a2bee24989' target=_blank style='color:#2F92EE;'>#Fasenra#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7249, encryptionId=a2bee24989, topicName=Fasenra)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb0b97, createdName=zhangxingru, createdTime=Sat Jan 13 13:06:00 CST 2018, time=2018-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589982, encodeId=55e915899822e, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63118, encryptionId=2d1c63118e9, topicName=欧盟批准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0d617780998, createdName=chenwq14, createdTime=Sat Jan 13 13:06:00 CST 2018, time=2018-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277630, encodeId=eba62e7630d2, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Thu Jan 11 22:28:13 CST 2018, time=2018-01-11, status=1, ipAttribution=)]
    2018-03-17 12498e5fm22(暂无昵称)

    #AZ#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2057947, encodeId=581e205e9474f, content=<a href='/topic/show?id=3836e24819' target=_blank style='color:#2F92EE;'>#FAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7248, encryptionId=3836e24819, topicName=FAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Wed Jun 27 12:06:00 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717835, encodeId=7e2a1e17835ea, content=<a href='/topic/show?id=e40c2116554' target=_blank style='color:#2F92EE;'>#严重哮喘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21165, encryptionId=e40c2116554, topicName=严重哮喘)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4b932466782, createdName=lujian, createdTime=Sat Apr 21 02:06:00 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1714758, encodeId=98371e14758db, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e5031899089, createdName=12498e5fm22(暂无昵称), createdTime=Sat Mar 17 19:06:00 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271166, encodeId=04c212e1166d7, content=<a href='/topic/show?id=a2bee24989' target=_blank style='color:#2F92EE;'>#Fasenra#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7249, encryptionId=a2bee24989, topicName=Fasenra)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb0b97, createdName=zhangxingru, createdTime=Sat Jan 13 13:06:00 CST 2018, time=2018-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589982, encodeId=55e915899822e, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63118, encryptionId=2d1c63118e9, topicName=欧盟批准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0d617780998, createdName=chenwq14, createdTime=Sat Jan 13 13:06:00 CST 2018, time=2018-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277630, encodeId=eba62e7630d2, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Thu Jan 11 22:28:13 CST 2018, time=2018-01-11, status=1, ipAttribution=)]
    2018-01-13 zhangxingru

    #Fasenra#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2057947, encodeId=581e205e9474f, content=<a href='/topic/show?id=3836e24819' target=_blank style='color:#2F92EE;'>#FAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7248, encryptionId=3836e24819, topicName=FAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Wed Jun 27 12:06:00 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717835, encodeId=7e2a1e17835ea, content=<a href='/topic/show?id=e40c2116554' target=_blank style='color:#2F92EE;'>#严重哮喘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21165, encryptionId=e40c2116554, topicName=严重哮喘)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4b932466782, createdName=lujian, createdTime=Sat Apr 21 02:06:00 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1714758, encodeId=98371e14758db, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e5031899089, createdName=12498e5fm22(暂无昵称), createdTime=Sat Mar 17 19:06:00 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271166, encodeId=04c212e1166d7, content=<a href='/topic/show?id=a2bee24989' target=_blank style='color:#2F92EE;'>#Fasenra#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7249, encryptionId=a2bee24989, topicName=Fasenra)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb0b97, createdName=zhangxingru, createdTime=Sat Jan 13 13:06:00 CST 2018, time=2018-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589982, encodeId=55e915899822e, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63118, encryptionId=2d1c63118e9, topicName=欧盟批准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0d617780998, createdName=chenwq14, createdTime=Sat Jan 13 13:06:00 CST 2018, time=2018-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277630, encodeId=eba62e7630d2, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Thu Jan 11 22:28:13 CST 2018, time=2018-01-11, status=1, ipAttribution=)]
    2018-01-13 chenwq14

    #欧盟批准#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2057947, encodeId=581e205e9474f, content=<a href='/topic/show?id=3836e24819' target=_blank style='color:#2F92EE;'>#FAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7248, encryptionId=3836e24819, topicName=FAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Wed Jun 27 12:06:00 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717835, encodeId=7e2a1e17835ea, content=<a href='/topic/show?id=e40c2116554' target=_blank style='color:#2F92EE;'>#严重哮喘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21165, encryptionId=e40c2116554, topicName=严重哮喘)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4b932466782, createdName=lujian, createdTime=Sat Apr 21 02:06:00 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1714758, encodeId=98371e14758db, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e5031899089, createdName=12498e5fm22(暂无昵称), createdTime=Sat Mar 17 19:06:00 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271166, encodeId=04c212e1166d7, content=<a href='/topic/show?id=a2bee24989' target=_blank style='color:#2F92EE;'>#Fasenra#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7249, encryptionId=a2bee24989, topicName=Fasenra)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb0b97, createdName=zhangxingru, createdTime=Sat Jan 13 13:06:00 CST 2018, time=2018-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589982, encodeId=55e915899822e, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63118, encryptionId=2d1c63118e9, topicName=欧盟批准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0d617780998, createdName=chenwq14, createdTime=Sat Jan 13 13:06:00 CST 2018, time=2018-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=277630, encodeId=eba62e7630d2, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Thu Jan 11 22:28:13 CST 2018, time=2018-01-11, status=1, ipAttribution=)]
    2018-01-11 orangesking

    好

    0